多种疾病患者血浆copeptin测定

Determination of Plasma Copeptin Levels in Some Cardiac and Pulmonary Disorders

目的:初步研究不同疾病患者血浆copeptin水平变化的意义。方法:我们对21位冠心病患者,16位哮喘病患者,17位肺癌患者以及30位年龄相符合的健康对照者的血浆copeptin水平进行了放射免疫分析(ra-dioimmunoassay,RIA)。结果:对比对照组,冠心病组和肺癌组显著升高(215±41 vs 54±4pg/ml,P<0.01;336±109 vs 54±4pg/ml,P<0.01),而哮喘病组虽有所升高(75±14 vs 54±4pg/ml),但差异无统计学意义(P>0.05)。结论:血浆copeptin水平的升高提示在冠心病和肺癌等疾病中血管加压素系统被激活,作为以上疾病的一个潜在的危险因子,在血浆copeptin水平升高时,对患者的早期干预可能具有重要的临床意义。

Objective To study the plasma copopfin levels in patients with some cardiac and pulmonary diseases. Methods Plasma levels of eopeptin were measured with RIA in 21 patients with CHD, 16 patents with asthma, 17 patients with lung cancer and 30 controls. Results The plasma levels of copeptin were significantly higher in CHD and lung cancer patents （215 ± 14 and 336 ± 109 vs 54 ±4pg/ml in controls, P 〈 0.01 ）, but were not significantly different from those in controls in patents with asthma （75 ± 14 vs 54 ± 4pg：/ml in controls, P 〉 0.05 ）. Conclusion The vasopressin system is aefvated in patients with CHD and lung cancer as indicated by changes in eopoptn a poptide derived from vasopressin precursor level. As a potential risk factor for those diseases, plasma eopeptin activation might have important prognoste significance.